Form SC 13G Sarepta Therapeutics, Filed by: Point72 Asset Management, L.P.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
Point72 Asset Management, L.P. Raises Stake in Sarepta Therapeutics (SRPT) to 5.3%
May 1, 2015 4:21 PM EDTIn a 13G filing on Sarepta Therapeutics (NASDAQ: SRPT), hedge fund Point72 Asset Management, L.P. disclosed a 5.3%, or 2,193,600 share, stake in the company. This is up 697.09% from the 275,200 shares held at the end of the latest quarter ending Dec. 31, 2015.
For more notable holders of Sarepta Therapeutics stock click here.
... More